Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleNuclear Oncology

PET 2-Fluoro-2-Deoxyglucose Uptake in Rat Prostate Adenocarcinoma During Chemotherapy with Gemcitabine

Uwe Haberkorn, Matthias E. Bellemann, Annette Altmann, Ludwig Gerlach, Iris Morr, Franz Oberdorfer, Gunnar Brix, Josef Doll, Johannes Blatter and Gerhard van Kaick
Journal of Nuclear Medicine August 1997, 38 (8) 1215-1221;
Uwe Haberkorn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias E. Bellemann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette Altmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludwig Gerlach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iris Morr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franz Oberdorfer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunnar Brix
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josef Doll
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Blatter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard van Kaick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 38, Issue 8
August 1, 1997
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PET 2-Fluoro-2-Deoxyglucose Uptake in Rat Prostate Adenocarcinoma During Chemotherapy with Gemcitabine
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PET 2-Fluoro-2-Deoxyglucose Uptake in Rat Prostate Adenocarcinoma During Chemotherapy with Gemcitabine
Uwe Haberkorn, Matthias E. Bellemann, Annette Altmann, Ludwig Gerlach, Iris Morr, Franz Oberdorfer, Gunnar Brix, Josef Doll, Johannes Blatter, Gerhard van Kaick
Journal of Nuclear Medicine Aug 1997, 38 (8) 1215-1221;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PET 2-Fluoro-2-Deoxyglucose Uptake in Rat Prostate Adenocarcinoma During Chemotherapy with Gemcitabine
Uwe Haberkorn, Matthias E. Bellemann, Annette Altmann, Ludwig Gerlach, Iris Morr, Franz Oberdorfer, Gunnar Brix, Josef Doll, Johannes Blatter, Gerhard van Kaick
Journal of Nuclear Medicine Aug 1997, 38 (8) 1215-1221;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Targeting the Internal Epitope of Prostate-Specific Membrane Antigen with 89Zr-7E11 Immuno-PET
  • Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline
  • Dominant Uptake of Fatty Acid over Glucose by Prostate Cells: A Potential New Diagnostic and Therapeutic Approach
  • Imaging of Cell Proliferation: Status and Prospects
  • Enhanced Apoptotic Reaction Correlates with Suppressed Tumor Glucose Utilization After Cytotoxic Chemotherapy: Use of 99mTc-Annexin V, 18F-FDG, and Histologic Evaluation
  • Rationale of 5-125I-Iodo-4'-Thio-2'-Deoxyuridine as a Potential Iodinated Proliferation Marker
  • 2-[18F]Fluoro-2-deoxyglucose and Glucose Uptake in Malignant Gliomas before and after Radiotherapy: Correlation with Outcome
  • Quantification of [18F]FDG Uptake in the Normal Liver Using Dynamic PET: Impact and Modeling of the Dual Hepatic Blood Supply
  • Google Scholar

More in this TOC Section

  • Dose Escalation Trial of Indium-111-Labeled Anti-Carcinoembryonic Antigen Chimeric Monoclonal Antibody (Chimeric T84.66) in Presurgical Colorectal Cancer Patients
  • Optimized Conditions for Chelation of Yttrium-90-DOTA Immunoconjugates
  • Quantifying the Radiation Dosage to Individual Skeletal Lesions Treated with Samarium-153-EDTMP
Show more Nuclear Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire